ETCAMAH Drug Patent Profile
Which patents cover Etcamah, and what generic alternatives are available?
Etcamah is a drug marketed by Astrazeneca and is included in one NDA. There are six patents protecting this drug.
The generic ingredient in ETCAMAH is camizestrant. One supplier is listed for this compound. Additional details are available on the camizestrant profile page.
DrugPatentWatch® Generic Entry Outlook for Etcamah
Etcamah will be eligible for patent challenges on September 4, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 22, 2041. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
US Patents and Regulatory Information for ETCAMAH
ETCAMAH is protected by six US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ETCAMAH is ⤷ Start Trial.
This potential generic entry date is based on patent 12,453,729.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | ETCAMAH | camizestrant | TABLET;ORAL | 220359-001 | Sep 4, 2026 | RX | Yes | Yes | 12,364,689 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca | ETCAMAH | camizestrant | TABLET;ORAL | 220359-001 | Sep 4, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astrazeneca | ETCAMAH | camizestrant | TABLET;ORAL | 220359-001 | Sep 4, 2026 | RX | Yes | Yes | 10,590,130 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ETCAMAH
When does loss-of-exclusivity occur for ETCAMAH?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1922
Estimated Expiration: ⤷ Start Trial
Australia
Patent: 21260109
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 2022021089
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 79912
Estimated Expiration: ⤷ Start Trial
Chile
Patent: 22002898
Estimated Expiration: ⤷ Start Trial
China
Patent: 5443128
Estimated Expiration: ⤷ Start Trial
Colombia
Patent: 22016378
Estimated Expiration: ⤷ Start Trial
Costa Rica
Patent: 220587
Estimated Expiration: ⤷ Start Trial
Denmark
Patent: 38787
Estimated Expiration: ⤷ Start Trial
Dominican Republic
Patent: 022000228
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 38787
Estimated Expiration: ⤷ Start Trial
Finland
Patent: 38787
Estimated Expiration: ⤷ Start Trial
Guatemala
Patent: 2200239
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 7218
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 19796
Estimated Expiration: ⤷ Start Trial
Patent: 23522247
Estimated Expiration: ⤷ Start Trial
Lithuania
Patent: 38787
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 0737
Estimated Expiration: ⤷ Start Trial
Patent: 22013258
Estimated Expiration: ⤷ Start Trial
Morocco
Patent: 388
Estimated Expiration: ⤷ Start Trial
Peru
Patent: 221838
Estimated Expiration: ⤷ Start Trial
Philippines
Patent: 022552755
Estimated Expiration: ⤷ Start Trial
Portugal
Patent: 38787
Estimated Expiration: ⤷ Start Trial
San Marino
Patent: 02600361
Estimated Expiration: ⤷ Start Trial
Serbia
Patent: 517
Estimated Expiration: ⤷ Start Trial
South Africa
Patent: 2212663
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 230005270
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 80216
Estimated Expiration: ⤷ Start Trial
Taiwan
Patent: 2206074
Estimated Expiration: ⤷ Start Trial
Patent: 93107
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ETCAMAH around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 109951 | ⤷ Start Trial | |
| Australia | 2017349797 | ⤷ Start Trial | |
| Brazil | 112019007393 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ETCAMAH
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3433256 | PA2026534 | Lithuania | ⤷ Start Trial | PRODUCT NAME: KAMIZESTRANTAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOSPAVIDALU; REGISTRATION NO/DATE: EU/1/26/2046 20260720 |
| 3433256 | C20265022 | Finland | ⤷ Start Trial | |
| 3433256 | CA 2026 00044 | Denmark | ⤷ Start Trial | PRODUCT NAME: CAMIZESTRANT, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTA; REG. NO/DATE: EU/1/26/2046 20260722 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
